6-[2-cyclobutyl-4-(2-dimethylamino-ethoxy)-3-propyl-phenyl]-pyridin-2-yl-amine | 1019636-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-[2-cyclobutyl-4-(2-dimethylamino-ethoxy)-3-propyl-phenyl]-pyridin-2-yl-amine
• 英文别名: 6-[2-Cyclobutyl-4-[2-(dimethylamino)ethoxy]-3-propylphenyl]pyridin-2-amine
• CAS: 1019636-78-2
• 化学式: C₂₂H₃₁N₃O
• 分子量: 353.508
• InChiKey: XYSSCNYXFSXWOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  51.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES
  申请人：——

  公开号：US20010007873A1

  公开（公告）日：2001-07-12

  This present invention relates to compounds of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  这项发明涉及公式1中定义的化合物，其中G、R1和R2如规范中所定义，以及含有它们的药物组合物，以及它们在治疗和预防中枢神经系统和其他疾病中的用途。
• [EN] LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE<br/>[FR] INTERMÉDIAIRES DE LACTONE DE NICOTINAMIDE RIBOSIDE ET DE NICOTINATE RIBOSIDE
  申请人：UNIV BELFAST

  公开号：WO2018033639A1

  公开（公告）日：2018-02-22

  The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.

  本发明涉及以下结构式的内酯，用作NAD的前体，并且它们的用途作为营养补充剂。
• [EN] PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE<br/>[FR] PRÉPARATION ET UTILISATION DE BÊTA-D-NICOTINAMIDE RIBOSIDE CRISTALLIN
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015186068A1

  公开（公告）日：2015-12-10

  Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicotinamide riboside chloride compositions may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, or for increasing insulin sensitivity in a subject.

  本文提供晶体质的β-D-烟酰胺核苷酸氯化物组合物的制备和使用方法。还提供相关的药物组合物及其使用方法。晶体质的β-D-烟酰胺核苷酸氯化物组合物可用于治疗需要提高NAD水平的疾病或疾病，包括线粒体疾病或疾病，胰岛素抵抗，代谢综合征，糖尿病，肥胖症或用于增加受试者胰岛素敏感性。
• 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
  申请人：Pfizer Inc.

  公开号：US20030162765A1

  公开（公告）日：2003-08-28

  This present invention relates to compounds of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  本发明涉及公式1的化合物，其中G、R1和R2如规范中所定义，以及含有它们的制药组合物，以及它们在治疗和预防中枢神经系统和其他疾病方面的用途。
• Modulators of CDC2-like kinases (CLKS) and methods of use thereof
  申请人：Milne Jill

  公开号：US20070248590A1

  公开（公告）日：2007-10-25

  Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.

  本文提供了使用Cdc2-like kinase (Clk)调节剂治疗和/或预防各种疾病和障碍的方法，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症、眼部疾病和/或潮红，以及需要增加线粒体活动的疾病或障碍。此外，提供了包含Clk调节化合物与另一种治疗剂联合使用的组合物。